Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Marimed (MRMD) Cash from Financing Activities (2016 - 2025)

Marimed (MRMD) has disclosed Cash from Financing Activities for 12 consecutive years, with -$944000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities fell 5.71% to -$944000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$4.7 million through Dec 2025, down 257.89% year-over-year, with the annual reading at -$4.7 million for FY2025, 257.89% down from the prior year.
  • Cash from Financing Activities for Q4 2025 was -$944000.0 at Marimed, up from -$1.7 million in the prior quarter.
  • The five-year high for Cash from Financing Activities was $23.3 million in Q1 2023, with the low at -$3.1 million in Q3 2023.
  • Average Cash from Financing Activities over 5 years is $1.4 million, with a median of -$307500.0 recorded in 2021.
  • The sharpest move saw Cash from Financing Activities crashed 1349.15% in 2022, then surged 7176.6% in 2023.
  • Over 5 years, Cash from Financing Activities stood at -$286000.0 in 2021, then plummeted by 109.79% to -$600000.0 in 2022, then surged by 850.0% to $4.5 million in 2023, then crashed by 119.84% to -$893000.0 in 2024, then dropped by 5.71% to -$944000.0 in 2025.
  • According to Business Quant data, Cash from Financing Activities over the past three periods came in at -$944000.0, -$1.7 million, and -$806000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.